Abstract:Background: Immune checkpoint blockade (ICB) is rapidly becoming a standard of care in the treatment of many cancer types. However, the subset of patients who respond to this type of therapy is limited. Another way to promote antitumoral immunity is the use of immunostimulatory molecules, such as cytokines or T cell co-stimulators. The systemic administration of immunotherapeutics leads to significant immune-related adverse events (irAEs), therefore, the localized antitumoral action is needed. One way to achieve this is intratumoral non-viral gene-immune therapy, which allows for prolonged and localized gene expression, and multiple drug administration. In this study, we combined the previously described non-viral gene delivery system, PEG-PEI-TAT copolymer, PPT, with murine OX40L-encoding plasmid DNA. Methods: The resulting OX40L/PPT nanoparticles were characterized via gel mobility assay, dynamic light scattering analysis and in vitro transfection efficiency evaluation. The antitumoral efficacy of intratumorally (i.t.) administered nanoparticles was estimated using subcutaneously (s.c.) implanted CT26 (colon cancer), B16F0 (melanoma) and 4T1 (breast cancer) tumor models. The dynamics of stromal immune cell populations was analyzed using flow cytometry. Weight loss and cachexia were used as irAE indicators. The effect of combination of i.t. OX40L/PPT with intraperitoneal PD-1 ICB was estimated in s.c. CT26 tumor model. Results: The obtained OX40L/PPT nanoparticles had properties applicable for cell transfection and provided OX40L protein expression in vitro in all three investigated cancer models. We observed that OX40L/PPT treatment successfully inhibited tumor growth in B16F0 and CT26 tumor models and showed a tendency to inhibit 4T1 tumor growth. In B16F0 tumor model, OX40L/PPT treatment led to the increase in antitumoral effector NK and T killer cells and to the decrease in pro-tumoral myeloid cells populations within tumor stroma. No irAE signs were observed in all 3 tumor models, which indicates good treatment tolerability in mice. Combining OX40L/PPT with PD-1 ICB significantly improved treatment efficacy in the CT26 subcutaneous colon cancer model, providing protective immunity against CT26 colon cancer cells. Conclusion: Overall, the anti-tumor efficacy observed with OX40L non-viral gene therapy, whether administered alone or in combination with ICB, highlights its potential to revolutionize cancer gene therapy, thus paving the way for unprecedented advancements in the cancer therapy field.

In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity

Reprogramming Macrophage by Targeting VEGF and CD40 Potentiates OX40 Immunotherapy

Gene-guided OX40L Anchoring to Tumor Cells for Synergetic Tumor “Self-Killing” Immunotherapy

OX40/OX40 ligand and its role in precision immune oncology

Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer

An Armed Oncolytic Virus Enhances the Efficacy of Tumor-Infiltrating Lymphocyte Therapy by Converting Tumors to Artificial Antigen-Presenting Cells in Situ.

Non-viral-mediated gene transfer of OX40 ligand for tumor immunotherapy

In Situ Tumor Cell Engineering Reverses Immune Escape to Enhance Immunotherapy Effect

Abstract 1718: Tumor Eradicated by an Effective in Situ Vaccine Based on a TLR Agonist and an Agonistic Anti-Ox40 Antibody

Nanomaterials Mediated Co‐Stimulation of toll‐like Receptors and CD40 for Antitumor Immunity

Therapeutic strategies for the costimulatory molecule OX40 in T-cell mediated immunity

Reprogramming Tumor-Associated Macrophages by Nanoparticle-Based Reactive Oxygen Species Photogeneration

Immune Checkpoint Reprogramming Via Sequential Nucleic Acid Delivery Strategy Optimizes Systemic Immune Responses for Gastrointestinal Cancer Immunotherapy

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

On-demand Integrated Nano-Engager Converting Cold Tumors to Hot Via Increased DNA Damage and Dual Immune Checkpoint Inhibition.

SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity

Development and Characterization of a Novel Anti-Ox40 Antibody for Potent Immune Activation

Nanoparticle-Mediated in Situ Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Generation and Characterization of a High‐affinity Chimeric Anti‐ox40 Antibody with Potent Antitumor Activity

Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy